TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›DERM›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Journey Medical Corp (DERM) financials

Income statement

Journey Medical Corp (DERM) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Revenue$44.5M$63.1M$71.0M$59.7M$55.1M$61.2M
Revenue growth—41.8%12.5%-16.0%-7.6%11.1%
Operating income$7.85M-$34.9M-$27.5M-$2.07M-$13.7M-$8.17M
Operating margin17.6%-55.2%-38.8%-3.5%-24.8%-13.3%
Net income$5.28M-$44.0M-$29.6M-$3.85M-$14.7M-$11.4M
Net margin11.9%-69.7%-41.7%-6.5%-26.6%-18.7%
EPS (diluted)$0.49-$4.32-$1.69-$0.21-$0.72-$0.47

Cash flow

Journey Medical Corp (DERM) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$5.13M-$2.18M-$13.5M$5.24M-$9.13M-$12.4M
Capital expenditures——$20.0M$5.00M$15.0M—
Free cash flow——-$33.5M$240K-$24.1M—

Balance sheet

Journey Medical Corp (DERM) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$8.25M$49.1M$32.0M$27.4M$20.3M$24.1M
Total assets$51.9M$97.3M$105M$76.8M$80.2M$94.6M
Total liabilities$41.6M$55.2M$88.2M$56.5M$60.2M$62.7M
Long-term debt——$19.8M$14.6M$24.9M$25.3M
Shareholders' equity$10.3M$42.0M$17.0M$20.4M$20.1M$31.9M
Retained earnings$5.12M-$38.9M-$68.5M-$72.4M-$87.0M-$98.5M
Shares (wtd avg diluted)10.8M10.2M17.5M18.2M20.4M24.5M

Every figure is extracted from Journey Medical Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Journey Medical Corp's annual revenue?
Journey Medical Corp (DERM) reported $61.2M of revenue for fiscal year 2025 — up 11.1% from $55.1M in FY2024, per its annual report filed with the SEC.
Is Journey Medical Corp profitable?
Not in FY2025 — DERM reported a net loss of $11.4M, per SEC filings.
Does DERM pay a dividend?
Journey Medical Corp reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full DERM analysis — verdict, score & filings →Is DERM a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.